BGJ398 for Bladder Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it does mention that you cannot use certain medications like those that increase phosphorus or calcium levels, strong CYP3A4 inducers or inhibitors, and some herbal preparations. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
How does the drug BGJ398 differ from other bladder cancer treatments?
BGJ398 is unique because it specifically targets and inhibits fibroblast growth factor receptors (FGFR1-3), which are often altered in bladder cancer. This oral medication is given in cycles of three weeks on and one week off, and it has shown effectiveness in reducing tumor size and stabilizing the disease in patients with FGFR3 alterations, offering a targeted approach compared to traditional chemotherapy.12345
What is the purpose of this trial?
The purpose of this study is to study the activity and effects of BGJ398 on bladder cancer tumors that are confined to the lining of the bladder.
Research Team
Jonathan Rosenberg, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults with recurrent high-risk bladder cancer that hasn't invaded muscle tissue and have had prior BCG therapy. They must be able to take oral meds, perform most daily activities (Karnofsky ≥80), use effective contraception if of childbearing potential, and not have certain health conditions like severe heart disease or active infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BGJ398 at a dose of 125 mg orally once daily on a three weeks on, one week off schedule
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BGJ398
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor